Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KOD NASDAQ:OKYO NASDAQ:ORPH NASDAQ:PHAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKODKodiak Sciences$9.78-2.8%$7.53$1.92▼$11.60$516.44M2.44450,738 shs211,099 shsOKYOOKYO Pharma$2.21+0.5%$2.68$0.90▼$3.35$83.12M-0.1165,159 shs11,511 shsORPHOrphazyme A/S$1.43$0.51▼$77.77$30.72M1.681.37 million shs941,400 shsPHARPharming Group$14.50-2.5%$11.86$7.06▼$17.08$993.67M0.056,577 shs13,208 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKODKodiak Sciences+2.76%+16.71%+27.34%+149.63%+322.69%OKYOOKYO Pharma-1.75%-5.39%-32.87%-5.79%+117.33%ORPHOrphazyme A/S0.00%0.00%0.00%0.00%0.00%PHARPharming Group+0.47%+6.48%+12.40%+28.58%+112.73%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKODKodiak Sciences$9.78-2.8%$7.53$1.92▼$11.60$516.44M2.44450,738 shs211,099 shsOKYOOKYO Pharma$2.21+0.5%$2.68$0.90▼$3.35$83.12M-0.1165,159 shs11,511 shsORPHOrphazyme A/S$1.43$0.51▼$77.77$30.72M1.681.37 million shs941,400 shsPHARPharming Group$14.50-2.5%$11.86$7.06▼$17.08$993.67M0.056,577 shs13,208 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKODKodiak Sciences+2.76%+16.71%+27.34%+149.63%+322.69%OKYOOKYO Pharma-1.75%-5.39%-32.87%-5.79%+117.33%ORPHOrphazyme A/S0.00%0.00%0.00%0.00%0.00%PHARPharming Group+0.47%+6.48%+12.40%+28.58%+112.73%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKODKodiak Sciences 2.00Hold$11.7520.18% UpsideOKYOOKYO Pharma 3.00Buy$7.00216.74% UpsideORPHOrphazyme A/S 0.00N/AN/AN/APHARPharming Group 3.00Buy$30.00106.84% UpsideCurrent Analyst Ratings BreakdownLatest OKYO, PHAR, KOD, and ORPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025KODKodiak SciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$3.00 ➝ $5.008/14/2025KODKodiak SciencesBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetUnderweight$4.00 ➝ $7.008/14/2025KODKodiak SciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Neutral$15.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKODKodiak SciencesN/AN/AN/AN/A$2.86 per shareN/AOKYOOKYO PharmaN/AN/AN/AN/A($0.16) per shareN/AORPHOrphazyme A/SN/AN/AN/AN/A$2.74 per shareN/APHARPharming Group$297.20M3.34$0.07 per share195.88$3.25 per share4.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKODKodiak Sciences-$176.21M-$3.80N/AN/AN/AN/A-155.27%-63.29%11/13/2025 (Estimated)OKYOOKYO Pharma-$4.71MN/A0.00N/AN/AN/AN/AN/AN/AORPHOrphazyme A/S-$97.01MN/A0.00N/AN/AN/AN/AN/AN/APHARPharming Group-$11.84M-$0.13N/A483.47N/A-2.19%-3.31%-1.78%10/23/2025 (Estimated)Latest OKYO, PHAR, KOD, and ORPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025KODKodiak Sciences-$1.01-$1.03-$0.02-$1.03N/AN/A7/31/2025Q2 2025PHARPharming Group-$0.10$0.06+$0.16$0.06$70.36 million$93.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKODKodiak SciencesN/AN/AN/AN/AN/AOKYOOKYO PharmaN/AN/AN/AN/AN/AORPHOrphazyme A/SN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKODKodiak SciencesN/A3.483.48OKYOOKYO PharmaN/A0.400.40ORPHOrphazyme A/S0.141.80N/APHARPharming Group0.382.792.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKODKodiak Sciences89.06%OKYOOKYO Pharma2.97%ORPHOrphazyme A/S10.74%PHARPharming Group0.03%Insider OwnershipCompanyInsider OwnershipKODKodiak Sciences45.90%OKYOOKYO Pharma40.46%ORPHOrphazyme A/SN/APHARPharming Group2.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKODKodiak Sciences9052.82 million28.58 millionOptionableOKYOOKYO Pharma737.61 million22.39 millionNot OptionableORPHOrphazyme A/S14135.31 millionN/ANot OptionablePHARPharming Group28068.51 million67.10 millionNot OptionableOKYO, PHAR, KOD, and ORPH HeadlinesRecent News About These CompaniesPharming Group promoted to the Euronext AMX® indexSeptember 10 at 6:02 AM | markets.businessinsider.comPharming Group N.V. (PHAR) Presents at H.C. Wainwright 27th Annual Global Investment Conference - SlideshowSeptember 8 at 2:02 PM | seekingalpha.comPharming Group (NASDAQ:PHAR) Shares Up 5% - Should You Buy?September 5, 2025 | marketbeat.comPharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Down 73.1% in AugustSeptember 5, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Shares Gap Down - Here's What HappenedSeptember 4, 2025 | marketbeat.comPharming Group to present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | finance.yahoo.comPharming Group names new finance headSeptember 2, 2025 | msn.comPharming Group appoints Kenneth Lynard as Chief Financial OfficerSeptember 2, 2025 | markets.businessinsider.comWall Street Analysts See a 142.26% Upside in Pharming Group (PHAR): Can the Stock Really Move This High?August 22, 2025 | zacks.comPharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Growth in Short InterestAugust 17, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Trading 1.2% Higher - Still a Buy?August 16, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Sees Large Volume Increase - Should You Buy?August 13, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Shares Gap Down - Should You Sell?August 12, 2025 | marketbeat.comPharming Group NV (PHARMA.XD) - Yahoo FinanceAugust 10, 2025 | finance.yahoo.comWall Street Analysts Think Pharming Group (PHAR) Could Surge 145.75%: Read This Before Placing a BetAugust 6, 2025 | zacks.comPharming Group N.V. Reports Strong Q2 EarningsAugust 4, 2025 | theglobeandmail.comPharming Group to participate in August investor conferenceAugust 4, 2025 | uk.finance.yahoo.comPharming Group Second Quarter 2025 Earnings: EPS: US$0.007 (vs US$0.002 loss in 2Q 2024)August 2, 2025 | finance.yahoo.comPharming Group N.V. (PHAR) Q2 2025 Earnings Call TranscriptAugust 1, 2025 | seekingalpha.comPharming Group N.V. 2025 Q2 - Results - Earnings Call PresentationAugust 1, 2025 | seekingalpha.comNew Strong Buy Stocks for August 1stAugust 1, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Biotech Catalysts Present Major OpportunityBy Nathan Reiff | August 25, 2025JNJ Stock Surge Signals Confidence in New Growth PathBy Jeffrey Neal Johnson | August 25, 20253 Under-the-Radar Biotechs Under $5 That Could Soar 200%By Chris Markoch | September 9, 2025CoreWeave and Madrigal's Insider Trades Flash Bullish SignalsBy Leo Miller | September 10, 2025OKYO, PHAR, KOD, and ORPH Company DescriptionsKodiak Sciences NASDAQ:KOD$9.78 -0.28 (-2.81%) Closing price 03:59 PM EasternExtended Trading$9.88 +0.11 (+1.10%) As of 04:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.OKYO Pharma NASDAQ:OKYO$2.19 -0.01 (-0.45%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.Orphazyme A/S NASDAQ:ORPHOrphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.Pharming Group NASDAQ:PHAR$14.50 -0.37 (-2.46%) Closing price 03:52 PM EasternExtended Trading$14.50 +0.00 (+0.01%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing Beyond DIY: Home Depot's Conquest of the Professional Market Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
